STOCK TITAN
  1. Home
  2. Sec-filings
  3. RXRX
  4. [Form 4] Recursion Pharmaceuticals, Inc. Insider Trading Activity

Recursion Pharmaceuticals CFO Maintains Strong Position with $4M+ in Stock

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ben R Taylor, Chief Financial Officer of Recursion Pharmaceuticals (RXRX), reported multiple securities transactions and holdings in a Form 4 filing:

Key Transaction: On June 16, 2025, Taylor disposed of 7,057 shares of Class A Common Stock at $4.92 per share through a tax withholding transaction (F code) related to RSU settlement. Following this transaction, Taylor directly owns 823,134 shares.

Stock Option Holdings:

  • 70,037 options at $7.25 (expires 2035)
  • 740,686 options at $6.09 (expires 2034)
  • 81,154 options at $0.14 (expires 2031)
  • 92,748 options at $0.06 (expires 2031)
  • 289,837 options at $0.04 (expires 2030)

All options have various vesting schedules ranging from monthly to annual installments, subject to continued service requirements.

Positive

  • None.

Negative

  • None.
Insider Taylor Ben R
Role Chief Financial Officer
Type Security Shares Price Value
Tax Withholding Class A Common Stock 7,057 $4.92 $35K
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
Holdings After Transaction: Class A Common Stock — 823,134 shares (Direct); Stock Option (Right to Buy) — 0 shares (Direct)
Footnotes (1)
  1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. 1/48th of the shares subject to the award vests and become exercisable on January 2, 2025, and each month thereafter, subject to Mr. Taylor's continued service through each vesting date. Twenty-five percent of the shares subject to the award vest and become exercisable on July 1, 2022, and the remaining shares subject to the award vest and become exercisable in quarterly installments thereafter, subject to Mr. Taylor's continued service through each vesting date. Twenty-five percent of the shares subject to the award vest and become exercisable on April 3, 2022, and the remaining shares subject to the award vest and become exercisable in quarterly installments thereafter, subject to Mr. Taylor's continued service through each vesting date. Twenty-five percent of the shares subject to the award vest and become exercisable on November 17, 2021, and the remaining shares subject to the award vest and become exercisable in annual installments thereafter, subject to Mr. Taylor's continued service through each vesting date.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Taylor Ben R
(Last) (First) (Middle)
41 S. RIO GRANDE STREET
(Street)
SALT LAKE CITY UT 84101
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 06/16/2025 F(1) 7,057 D $4.92 823,134 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $7.25 (2) 02/03/2035 Class A Common Stock 0 70,037 D
Stock Option (Right to Buy) $6.09 (3) 12/18/2034 Class A Common Stock 0 740,686 D
Stock Option (Right to Buy) $0.14 (4) 07/01/2031 Class A Common Stock 0 81,154 D
Stock Option (Right to Buy) $0.06 (5) 04/02/2031 Class A Common Stock 0 92,748 D
Stock Option (Right to Buy) $0.04 (6) 11/26/2030 Class A Common Stock 0 289,837 D
Explanation of Responses:
1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
2. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
3. 1/48th of the shares subject to the award vests and become exercisable on January 2, 2025, and each month thereafter, subject to Mr. Taylor's continued service through each vesting date.
4. Twenty-five percent of the shares subject to the award vest and become exercisable on July 1, 2022, and the remaining shares subject to the award vest and become exercisable in quarterly installments thereafter, subject to Mr. Taylor's continued service through each vesting date.
5. Twenty-five percent of the shares subject to the award vest and become exercisable on April 3, 2022, and the remaining shares subject to the award vest and become exercisable in quarterly installments thereafter, subject to Mr. Taylor's continued service through each vesting date.
6. Twenty-five percent of the shares subject to the award vest and become exercisable on November 17, 2021, and the remaining shares subject to the award vest and become exercisable in annual installments thereafter, subject to Mr. Taylor's continued service through each vesting date.
Remarks:
/s/ Kyle Nelson, attorney-in-fact 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many RXRX shares were disposed of by CFO Ben Taylor on June 16, 2025?

CFO Ben Taylor disposed of 7,057 shares of Class A Common Stock on June 16, 2025 at a price of $4.92 per share. These shares were withheld by Recursion Pharmaceuticals for tax withholding purposes related to the settlement of restricted stock units.

What is the total number of RXRX shares owned by CFO Ben Taylor after the June 2025 transaction?

Following the reported transaction, Ben Taylor directly owned 823,134 shares of RXRX Class A Common Stock.

What stock options does Ben Taylor hold in RXRX as of June 2025?

Ben Taylor holds multiple stock option grants: 70,037 shares at $7.25 (expires 2035), 740,686 shares at $6.09 (expires 2034), 81,154 shares at $0.14 (expires 2031), 92,748 shares at $0.06 (expires 2031), and 289,837 shares at $0.04 (expires 2030).

What is the vesting schedule for RXRX CFO Ben Taylor's most recent stock option grant?

The most recent stock option grant (at $7.25 exercise price) vests as to 1/48th of the shares on March 1, 2025, with 1/48th of the shares vesting monthly thereafter.